

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5661406
<b>Application Number:</b>	09820158
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4965
<b>Title of Invention:</b>	ESTROGEN AGONISTS/ANTAGONISTS FOR PREVENTING BREAST CANCER
<b>First Named Inventor/Applicant Name:</b>	Kimberly O. Cameron
<b>Correspondence Address:</b>	Gregg C. Benson Pfizer Inc. Patent Department, MS 4159 Eastern Point Road Groton CT 06340 US 8604414901 -
<b>Filer:</b>	John Anthony Wichtowski/Margaret Abbott
<b>Filer Authorized By:</b>	John Anthony Wichtowski
<b>Attorney Docket Number:</b>	PC8835ETMC
<b>Receipt Date:</b>	08-JUL-2009
<b>Filing Date:</b>	28-MAR-2001
<b>Time Stamp:</b>	11:29:47
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 940

RAM confirmation Number	7413				
Deposit Account	161445				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)					
<b>File Listing:</b>					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		PC8835E-Response-7-8-09.pdf	79828 4e349c3b8b4f7531377b7e315d6a14a9f6657144	yes	6
	<b>Multipart Description/PDF files in .zip description</b>				
	<b>Document Description</b>		<b>Start</b>	<b>End</b>	
	Amendment After Final		1	1	
	Applicant Arguments/Remarks Made in an Amendment		2	6	
<b>Warnings:</b>					
<b>Information:</b>					
2	Rule 130, 131 or 132 Affidavits	PC8835E-132DECLARATION.pdf	34686 7881079e52fd4579332baf7b5796afaba7393b60	no	2
<b>Warnings:</b>					
<b>Information:</b>					
3	Request for Continued Examination (RCE)	PC8835E-REC-sb0030e_fill2.pdf	236663 eb8b5d2ad3aa44977c1b53209d7cec63bd4e308b1	no	2
<b>Warnings:</b>					
This is not a USPTO supplied RCE SB30 form.					
<b>Information:</b>					
4	Extension of Time	PC8835E-Extension-Time-One-Month-sb0022i.pdf	231420 3e0169b29794c5feaf7d4e1360a9f34286a587e4	no	1
<b>Warnings:</b>					
<b>Information:</b>					
5	Fee Worksheet (PTO-875)	fee-info.pdf	32479 880607124b5678095b3d07267832cfc15ad591f4	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			615076		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**